阿霉素联合地塞米松玻璃体内注射的临床应用  

Intravitreal injection of doxorobicin and dexamethason in treatment of proliferative vitreoretinopathy

作　　者：荣翱[1] 李锦文[1] 

机构地区：[1]同济大学附属同济医院眼科,上海200065

出　　处：《中华医学杂志》2002年第8期546-548,共3页National Medical Journal of China

摘　　要：目的　应用阿霉素、地塞米松术中注入玻璃体腔 ,观察对增生性玻璃体视网膜病变PVR的抑制作用。方法　对 4 2眼视网膜脱离伴PVR的患者施行手术加玻璃体腔药物注射 ,与单纯手术组30眼视网膜脱离伴PVR作对比分析 ,并行有关血流动力学观察。结果手术加注药物组与单纯手术组比较 ,术后 3～ 5个月视网膜表面增生膜和网膜下机化膜比术前加重的发生率分别为 :7 1%和 2 6 7%(P <0 0 5 )。两组环扎术均可导致眼部血流动力学改变 ,术后 1～ 2周的视网膜中央动脉 (CRA)和中央静脉 (CRV)的收缩期最大平均流速分别为 6 3cm/s± 2 5cm/s和 4 8cm/s± 1 4cm/s ,比正常值分别下降 33 7%和 16 7%。Objectives To investigate the inhibitory effect of intravitreal injection of doxorubicin and dexamethason on proliferative vitreoretinopathy (PVR). Methods Forty two eyes with retinal detachment complicated with proliferative vitreoretinopathy underwent surgery and intravitreal injection of doxorubicin and dexamethason and followed up for 3～5 months. The curative effect was compared with that of pure surgery on 30 eyes with retinal detachment complicated with PVR. Relevant hemodynamic changes of central retinal artery (CRA) and central retinal vein (CRV) were also evaluated. Results Retinal reattachment was found in most eyes in both groups postoperatively. The worsening rate of epiretinal membrane and subretinal membrane was 7 1% and 26 7% in the surgery plus injection group and pure surgery group respectively ( P <0 05). The maximum average systole flow rate of CRA and CRV were 6 3 cm/s±2 5 cm/s and 4 8 cm/s±1 4 cm/s, 33 7% and 16 7% than normal value respectively. Conclusion Intravitreal injection of doxorubicin and dexamethason is effective against proliferative vitreoretinopathy.

关 键 词：阿霉素 地塞米松 玻璃体内注射 增生性玻璃体视网膜病 PVR 

分 类 号：R774.1[医药卫生—眼科] R978.1[医药卫生—临床医学]